Antileukemic effect of L-aspartyl-hydrazine.
Beta-L-aspartyl-hydrazine can significantly prolong survival of the A mouse strain infected with a lymphatic leukemia sensitive to L-asparaginase. By combining the above substance with L-asparaginase even better results can be obtained.
D000818:Animals; D001215:Asparaginase / Q000008:administration & dosage / Q000627:therapeutic use; D001224:Aspartic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D006834:Hydrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D007942:Leukemia, Experimental; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D051379:Mice; D012510:Sarcoma 180 / Q000188:drug therapy
D006834:Hydrazines; C010682:beta-L-aspartyl-hydrazine; D001224:Aspartic Acid; D001215:Asparaginase